Jokhang
2021-08-26
[Miser]
Gilead Gets $1.2 Billion Patent Loss to Bristol-Myers Overturned
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
3
2
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":810432273,"tweetId":"810432273","gmtCreate":1629990965992,"gmtModify":1704954334354,"author":{"id":3586392338558856,"idStr":"3586392338558856","authorId":3586392338558856,"authorIdStr":"3586392338558856","name":"Jokhang","avatar":"https://static.tigerbbs.com/d189ae3ec01747be0bd951c14c32cb94","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":8,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p><span>[Miser] </span><br></p></body></html>","htmlText":"<html><head></head><body><p><span>[Miser] </span><br></p></body></html>","text":"[Miser]","highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":3,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/810432273","repostId":1143350451,"repostType":4,"repost":{"id":"1143350451","kind":"news","pubTimestamp":1629990393,"share":"https://www.laohu8.com/m/news/1143350451?lang=&edition=full","pubTime":"2021-08-26 23:06","market":"us","language":"en","title":"Gilead Gets $1.2 Billion Patent Loss to Bristol-Myers Overturned","url":"https://stock-news.laohu8.com/highlight/detail?id=1143350451","media":"Bloomberg","summary":"Bristol-Myers patent on immunotherapy invalidated by court\nDispute is over revolutionary technique t","content":"<ul>\n <li>Bristol-Myers patent on immunotherapy invalidated by court</li>\n <li>Dispute is over revolutionary technique to fight cancer</li>\n</ul>\n<p>Gilead Sciences Inc. persuaded a U.S. appeals court to reverse a $1.2 billion judgment Bristol-Myers Inc. had won over revolutionary treatments that use a body’s own immune system to fight cancer.</p>\n<p>The patent owned by Bristol-Myers’s Juno Therapeutics and the Sloan Kettering Institute for Cancer Research is invalid, the U.S. Court of Appeals for the Federal Circuit ruled. The jury verdict that upheld the patent was “not supported by substantial evidence,” the three-judge panel ruled.</p>\n<p>The fight was over a pioneering technique known as CAR-T, in which the T cells of a person’s own immune system are modified to attack cancer cells. Gilead’s Kite unit makes Yescarta for the treatment of certain types of large B-cell lymphoma, a blood cancer.</p>\n<p>Kite successfully argued that the patent didn’t adequately describe an invention and instead would “cover an enormous number (millions of billions)” of potential candidates. The patent’s “written description contains scant details” of which specific antibody would work, Chief Judge Kimberly Moore wrote for the court.</p>\n<p>A Bristol-Myers spokesperson didn’t immediately comment. Representatives of Gilead didn’t immediately respond to a request for comment.</p>\n<p>Immunotherapy helped spur a takeover bonanza in the drug industry, including Gilead’s $12 billion purchase of Kite in 2017. Juno, which holds the license to the patent at the heart of the trial, wasboughtbyCelgene Corp.for $9 billion in 2018 and Celgene in turn was bought by Bristol-Myers for $74 billion.</p>\n<p>The dispute started when Juno and Kite were both standalone companies, even before Yescarta went on sale. Bristol-Myers argued that Kite copied a treatment that had been developed by researchers at Memorial Sloan Kettering Cancer Center and licensed to Juno for development of a cancer treatment. Juno and Sloan Kettering filed this lawsuit on the same day that Yescarta received U.S. regulatory approval.</p>\n<p>The jury initially awarded $585 million in damages plus a 27.6% running royalty on sales of Yescarta. The damage award latergrewto $1.2 billion after enhanced damages.</p>\n<p>The case is Juno Therapeutics Inc. v. Kite Pharma Inc., U.S. Court of Appeals for the Federal Circuit (Washington).</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gilead Gets $1.2 Billion Patent Loss to Bristol-Myers Overturned</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGilead Gets $1.2 Billion Patent Loss to Bristol-Myers Overturned\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-26 23:06 GMT+8 <a href=https://www.bloomberg.com/news/articles/2021-08-26/gilead-wins-reversal-of-1-2b-patent-loss-to-bristol-myers?srnd=markets-vp><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Bristol-Myers patent on immunotherapy invalidated by court\nDispute is over revolutionary technique to fight cancer\n\nGilead Sciences Inc. persuaded a U.S. appeals court to reverse a $1.2 billion ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-08-26/gilead-wins-reversal-of-1-2b-patent-loss-to-bristol-myers?srnd=markets-vp\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BMY":"施贵宝","GILD":"吉利德科学"},"source_url":"https://www.bloomberg.com/news/articles/2021-08-26/gilead-wins-reversal-of-1-2b-patent-loss-to-bristol-myers?srnd=markets-vp","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1143350451","content_text":"Bristol-Myers patent on immunotherapy invalidated by court\nDispute is over revolutionary technique to fight cancer\n\nGilead Sciences Inc. persuaded a U.S. appeals court to reverse a $1.2 billion judgment Bristol-Myers Inc. had won over revolutionary treatments that use a body’s own immune system to fight cancer.\nThe patent owned by Bristol-Myers’s Juno Therapeutics and the Sloan Kettering Institute for Cancer Research is invalid, the U.S. Court of Appeals for the Federal Circuit ruled. The jury verdict that upheld the patent was “not supported by substantial evidence,” the three-judge panel ruled.\nThe fight was over a pioneering technique known as CAR-T, in which the T cells of a person’s own immune system are modified to attack cancer cells. Gilead’s Kite unit makes Yescarta for the treatment of certain types of large B-cell lymphoma, a blood cancer.\nKite successfully argued that the patent didn’t adequately describe an invention and instead would “cover an enormous number (millions of billions)” of potential candidates. The patent’s “written description contains scant details” of which specific antibody would work, Chief Judge Kimberly Moore wrote for the court.\nA Bristol-Myers spokesperson didn’t immediately comment. Representatives of Gilead didn’t immediately respond to a request for comment.\nImmunotherapy helped spur a takeover bonanza in the drug industry, including Gilead’s $12 billion purchase of Kite in 2017. Juno, which holds the license to the patent at the heart of the trial, wasboughtbyCelgene Corp.for $9 billion in 2018 and Celgene in turn was bought by Bristol-Myers for $74 billion.\nThe dispute started when Juno and Kite were both standalone companies, even before Yescarta went on sale. Bristol-Myers argued that Kite copied a treatment that had been developed by researchers at Memorial Sloan Kettering Cancer Center and licensed to Juno for development of a cancer treatment. Juno and Sloan Kettering filed this lawsuit on the same day that Yescarta received U.S. regulatory approval.\nThe jury initially awarded $585 million in damages plus a 27.6% running royalty on sales of Yescarta. The damage award latergrewto $1.2 billion after enhanced damages.\nThe case is Juno Therapeutics Inc. v. Kite Pharma Inc., U.S. Court of Appeals for the Federal Circuit (Washington).","news_type":1},"isVote":1,"tweetType":1,"viewCount":142,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":7,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/810432273"}
精彩评论